[go: up one dir, main page]

PE20090653A1 - Formulacion inmunogenica, porque comprende una cepa recombinante atenuada de mycobacterium, preferentemente la cepa recombinante bacilo de calmette y guerin (bcg), que expresa al menos una proteina o fragmento inmunogenico del virus respiratorio sinc - Google Patents

Formulacion inmunogenica, porque comprende una cepa recombinante atenuada de mycobacterium, preferentemente la cepa recombinante bacilo de calmette y guerin (bcg), que expresa al menos una proteina o fragmento inmunogenico del virus respiratorio sinc

Info

Publication number
PE20090653A1
PE20090653A1 PE2008001628A PE2008001628A PE20090653A1 PE 20090653 A1 PE20090653 A1 PE 20090653A1 PE 2008001628 A PE2008001628 A PE 2008001628A PE 2008001628 A PE2008001628 A PE 2008001628A PE 20090653 A1 PE20090653 A1 PE 20090653A1
Authority
PE
Peru
Prior art keywords
recombinant strain
respiratory
vrs
immunogenic
mycobacterium
Prior art date
Application number
PE2008001628A
Other languages
English (en)
Inventor
Parra Alexis Mikes Kalegis
Munoz Pablo Alberto Gonzalez
Ramirez Susan Marcela Bueno
Original Assignee
Univ Pontificia Catolica Chile
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Pontificia Catolica Chile filed Critical Univ Pontificia Catolica Chile
Publication of PE20090653A1 publication Critical patent/PE20090653A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

SE REFIERE A UNA FORMULACION INMUNOGENICA QUE CONTIENE: A) UNA CEPA RECOMBINANTE ATENUADA DE MYCOBACTERIUM DE LA CEPA BACILO DE CALMETTE Y GUERIN (BCG) EN UNA CONCENTRACION DE 104-109 BACTERIAS, QUE EXPRESA AL MENOS UNA PROTEINA O FRAGMENTO INMUNOGENICO DEL VIRUS RESPIRATORIO SINCICIAL (VRS), EN UNA SOLUCION TAMPON SALINA. DONDE LOS GENES QUE CODIFICAN PARA LAS PROTEINAS VRS SE ENCUENTRAN INSERTOS EN EL GENOMA DEL MYCOBACTERIUM Y DICHAS PROTEINAS VRS PERTENECEN A LOS SUBTIPOS VRS A O VRS B O AMBOS. DICHA FORMULACION PUEDE SER UTILIZADA CON OTRAS FORMULACIONES INMUNOGENICAS, Y ES FORMULADA PARA SU ADMINISTRACION SUBCUTANEA, PERCUTANEA O SUBDERMICA EN SOLUCION SALINA FISIOLOGICA SIENDO UTIL PARA TRATAR INFECCIONES CAUSADAS POR EL VIRUS RESPIRATORIO SINCICIAL (VRS)
PE2008001628A 2007-09-20 2008-09-18 Formulacion inmunogenica, porque comprende una cepa recombinante atenuada de mycobacterium, preferentemente la cepa recombinante bacilo de calmette y guerin (bcg), que expresa al menos una proteina o fragmento inmunogenico del virus respiratorio sinc PE20090653A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CL2007002710A CL2007002710A1 (es) 2007-09-20 2007-09-20 Formulacion inmunogenica que confiere proteccion contra la infeccion o patologia causada por el virus respiratorio sincicial (vrs) que comprende una cepa recombinante atenuada de mycobacterium; y uso de la formulacion inmunogenica para preparar una vacuna para prevenir, tratar o atenuar infecciones del vrs.

Publications (1)

Publication Number Publication Date
PE20090653A1 true PE20090653A1 (es) 2009-06-20

Family

ID=51399051

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008001628A PE20090653A1 (es) 2007-09-20 2008-09-18 Formulacion inmunogenica, porque comprende una cepa recombinante atenuada de mycobacterium, preferentemente la cepa recombinante bacilo de calmette y guerin (bcg), que expresa al menos una proteina o fragmento inmunogenico del virus respiratorio sinc

Country Status (10)

Country Link
US (1) US8398993B2 (es)
EP (1) EP2207567B1 (es)
CN (1) CN101918029B (es)
AR (2) AR067425A1 (es)
CL (1) CL2007002710A1 (es)
DK (1) DK2207567T3 (es)
ES (1) ES2528197T3 (es)
PE (1) PE20090653A1 (es)
PL (1) PL2207567T3 (es)
WO (1) WO2009039178A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102021149B (zh) * 2010-07-27 2013-04-24 张卫东 基因ns1缺陷型呼吸道合胞病毒及其治疗肺癌的应用
JP2015514132A (ja) 2012-04-10 2015-05-18 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア ヒト呼吸器合胞体ウイルスコンセンサス抗原、核酸構築物、およびそれらから作製されるワクチン、ならびにその使用方法
WO2014005643A1 (en) * 2012-07-05 2014-01-09 Okairos Ag Novel prime-boosting regimens involving immunogenic polypeptides encoded by polynucleotides
CL2013002829A1 (es) * 2013-10-01 2014-04-04 Univ Pontificia Catolica Chile Formulacion inmunogenica que contiene bcg vivas recombinantes que expresan antigenos de metapneumovirus (hmpv) en una suspension que se prepara a partir de un liofilizado sin la necesidad de adjuvante; su uso farmaceutico; vacuna contra hmpv.
EP3154576A1 (en) 2014-06-13 2017-04-19 GlaxoSmithKline Biologicals S.A. Immunogenic combinations
CN104593389A (zh) * 2015-01-27 2015-05-06 吉林大学 一种重组合胞病毒蛋白及其应用
CL2019003847A1 (es) * 2019-12-26 2021-08-06 Univ Pontificia Catolica Chile Nuevo uso de formulación inmunogénica bcg que expresa una proteína de virus respiratorio sincicial contra hmpv
CL2020000857A1 (es) * 2020-03-31 2021-11-05 Univ Pontificia Catolica Chile Nuevo uso de formulación inmunogénica bcg que expresa una proteína del virus respiratorio sincicial humano contra bvrs en bovinos
CN114748615A (zh) * 2022-04-29 2022-07-15 成都安永鼎业生物技术有限公司 一种治疗用重组卡介苗的冻干制剂及其制备方法和用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2111217A1 (en) * 1991-06-13 1992-12-23 Albert Einstein College Of Medicine, A Division Of Yehiva University Insertional mutations in mycobacteria
US6566121B1 (en) * 1991-06-13 2003-05-20 Albert Einstein College Of Medicine Of Yeshiva University Insertional mutations in mycobacteria
US20020081317A1 (en) * 1999-02-02 2002-06-27 Mahan Michael J. Bacteria with altered DNA adenine methylase (DAM) activity and heterologous epitope
WO2002009749A2 (en) * 2000-07-31 2002-02-07 Aventis Pasteur Limited Respiratory syncytial virus vaccine
CN1297316C (zh) * 2001-06-07 2007-01-31 惠氏控股有限公司 作为佐剂的霍乱全毒素的突变体形式
US7070786B2 (en) * 2003-06-06 2006-07-04 Centocor, Inc. RSV proteins, antibodies, compositions, methods and uses
EP1830877A2 (en) * 2004-12-01 2007-09-12 Aeras Global TB Vaccine Foundation Recombinant bcg strains with attenuated immunosuppresive properties

Also Published As

Publication number Publication date
AR116662A2 (es) 2021-06-02
EP2207567B1 (en) 2014-11-05
DK2207567T3 (en) 2015-01-26
CN101918029B (zh) 2015-05-20
EP2207567A1 (en) 2010-07-21
ES2528197T3 (es) 2015-02-05
CN101918029A (zh) 2010-12-15
WO2009039178A1 (en) 2009-03-26
EP2207567A4 (en) 2013-05-01
PL2207567T3 (pl) 2015-06-30
US8398993B2 (en) 2013-03-19
US20110200634A1 (en) 2011-08-18
CL2007002710A1 (es) 2008-01-04
AR067425A1 (es) 2009-10-14

Similar Documents

Publication Publication Date Title
PE20090653A1 (es) Formulacion inmunogenica, porque comprende una cepa recombinante atenuada de mycobacterium, preferentemente la cepa recombinante bacilo de calmette y guerin (bcg), que expresa al menos una proteina o fragmento inmunogenico del virus respiratorio sinc
BR112017017949A2 (pt) regimes de iniciação-reforço envolvendo administração de pelo menos um constructo de mrna
AU2018240515A1 (en) Nucleic acids encoding CRISPR-associated proteins and uses thereof
AR089797A1 (es) Vacunas contra clostridum difficile que comprenden toxinas recombinantes
BR112016016290A2 (pt) Composições farmacêuticas de insulina de ação rápida, conjunto de infusão, sistema de conjunto de infusão e usos de análogos monoméricos ou diméricos de insulina
BR112018073676A2 (pt) lipossomas peguilados e métodos de uso
NZ616304A (en) Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
BR112015014462A2 (pt) vetorização farmacêutica de uma via de sinalização de dinucleotídeos cíclicos de mamíferos
BR112016029582A2 (pt) derivados de exendina-4 como agonistas de receptor de glucagon seletivos
BR112022017308A2 (pt) Composição que compreende lactoferrina e cepas bacterianas probióticas para uso oral com ação antiviral
BR112015025464A2 (pt) coagonistas do receptor de glp-1/glucagon estáveis, prolongados para uso médico
BR112013032251A2 (pt) composição estável da vacina da cepa do vírus chikungunya inativado com uma ou mais mutações; método para induzir uma resposta imune protetora em indivíduos humanos contra infecções causadas pelo vírus chikungunya; uso de isolados do vírus chikungunya; composição combinada da vacina
BR112012027315A2 (pt) polipeptídeo quimérico, composição, molécula de ácido nucleico quimérica, vetor, célula hospedeira, processo de produção de um polipeptídeo, vacina combinada, e, métodos para a indução de uma resposta imunológica e para prevenir ou tratar uma infecção ou doença
AR090470A1 (es) Vacuna contra el virus sincicial respiratorio (rsv)
AR065076A1 (es) Vacuna contra el papilomavirus
MX2021002586A (es) Dosis unitaria de vacuna contra el dengue y administracion de esta.
MX2020005235A (es) Celula humana transformada y uso de la misma.
BR112014017141A2 (pt) método de tratamento de diabetes usando-se apolipoproteína a-iv não glicosilada
AR093185A1 (es) Virus prrs (sindrome reproductivo y respiratorio porcino) que induce al interferon tipo i en celulas susceptibles
BR112022000710A2 (pt) Vacina viral terapêutica
BR112015019568A2 (pt) Peptídeo isolado, composição compreendendo o mesmo e uso do mesmo
BR112017022755A2 (pt) formulações de glucopiranosil lipídeo a e alérgeno a amendoim para administração sublingual
BR112015017903A2 (pt) vacina de subunidade de mycobacterium avium subsp. paratuberculosis única ou de múltiplos estágios
BR112015031226A2 (pt) Composição de vacina, e, uso da composição de vacina
AR094810A1 (es) Parvovirus porcino 5b, métodos de uso y vacuna

Legal Events

Date Code Title Description
FG Grant, registration